Loading
Acute Myeloid Leukemia Research / Bone Metabolism and Diseases · Journal article
npj Drug Discovery. · September 7, 2026
Raises a question worth testing. It does not answer one.
This is a preclinical exploration of CADD522, a RUNX2 inhibitor, in a murine ovariectomy model of post-menopausal bone loss. The compound demonstrated improved bone formation, preserved trabecular microarchitecture, reduced marrow and peripheral adiposity, and acceptable short-term tolerability with oral bioavailability; however, these findings are limited to animal studies and do not yet support clinical use.
Preclinical animal model study with pharmacokinetic and toxicological assessment. Female mice with ovariectomy-induced post-menopausal bone loss model.. Intervention: CADD522 (small molecule RUNX2 inhibitor) at 25 mg/kg, orally, three times weekly for eight weeks.
CADD522 at 25 mg/kg, three times weekly for eight weeks, enhanced bone formation and preserved trabecular microarchitecture in ovariectomy-induced mice Treatment reduced marrow and peripheral adiposity in the same model Cellular thermal shift assays confirmed direct engagement of RUNX2 target
Long-term tolerability and efficacy beyond eight weeks not assessed; rapid systemic clearance may limit clinical utility. Oral bioavailability demonstrated with favourable short-term tolerability despite rapid systemic clearance
This preclinical finding does not yet have direct clinical implications. CADD522 requires progression through human clinical trials to establish safety, efficacy, and optimal dosing in post-menopausal women before any clinical recommendation can be made.
Preclinical mechanistic study in an animal model with no clinical trial data, demonstrating target engagement and a potential therapeutic approach requiring confirmation in human subjects.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding does not yet have direct clinical implications. CADD522 requires progression through human clinical trials to establish safety, efficacy, and optimal dosing in post-menopausal women before any clinical recommendation can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Osteoporosis is a leading cause of age-related morbidity, yet existing antiresorptive and anabolic therapies remain limited by safety concerns, contraindications and poor long-term adherence. CADD522 is a small molecule inhibitor of the RUNX2 transcription factor currently under development for cancer therapy. Here, we investigated whether RUNX2 inhibition could protect against post-menopausal bone loss. In an ovariectomy-induced mouse model, CADD522 (25 mg/kg, three times weekly for eight weeks) enhanced bone formation, preserved trabecular microarchitecture and reduced marrow and peripheral adiposity. Cross-species pharmacokinetic and toxicological studies demonstrated oral bioavailability, favourable short-term tolerability and target engagement despite rapid systemic clearance, while cellular thermal shift assays confirmed direct engagement of RUNX2. Together, these findings identify RUNX2 inhibition as a therapeutic strategy that simultaneously improves skeletal integrity and metabolic homeostasis, supporting further development of CADD522 for osteoporosis and other RUNX2-driven diseases.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.